Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side‐effects in patients with psoriasis treated with adalimumab,etanercept or ustekinumab in daily practice: a prospective,comparative, long‐term drug‐survival study from the BioCAPTURE registry期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side‐effects in patients with psoriasis treated with adalimumab,etanercept or ustekinumab in daily practice: a prospective,comparative, long‐term drug‐survival study from the BioCAPTURE registry

Authors:	J. Zweegers J.M.P.A. van den Reek P.C.M. van de Kerkhof M.E. Otero A.L.A. Kuijpers M.I.A. Koetsier W.P. Arnold M.A.M. Berends L. Weppner‐Parren P.M. Ossenkoppele M.D. Njoo J.M. Mommers P.P.M. van Lümig R.J.B. Driessen W. Kievit E.M.G.J. de Jong

Affiliation:	1. Department of Dermatology, Biostatistics and Health Technology Assessment, Radboud University Medical Center, Nijmegen, the Netherlands;2. Maxima Medisch Centrum, Eindhoven/Veldhoven, the Netherlands;3. Gelre Ziekenhuizen, Apeldoorn, the Netherlands;4. Ziekenhuis Gelderse Vallei, Ede, the Netherlands;5. Slingeland Ziekenhuis, Doetinchem, the Netherlands;6. Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands;7. Ziekenhuisgroep Twente, Almelo, Hengelo, the Netherlands;8. St Anna Ziekenhuis, Geldrop, the Netherlands;9. Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Medical Center, Nijmegen, the Netherlands;10. Radboud University, Nijmegen, the Netherlands

Abstract:

Keywords: